Perdue J F, LeBon T R, Kato J, Hampton B, Fujita-Yamaguchi Y
Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross, Rockville, Maryland 20855.
Endocrinology. 1991 Dec;129(6):3101-8. doi: 10.1210/endo-129-6-3101.
In a study that was reported from this laboratory, the mitogenic potency of an apparent mol wt (appMr) of 15,000 precursor form of human insulin-like growth factor-II (hIGF-II) was shown to be greater than that of completely processed hIGF-II for human fetal-derived fibroblasts, and both were more potent than rIGF-I. Since it is generally acknowledged that the stimulation of cell replication by the IGFs is mediated by IGF-I receptors, we undertook to determine whether differences between the receptors' affinity for the two Mr forms of hIGF-II and recombinant IGF-I (rIGF-I) or between its efficiency to couple specific growth factor occupancy to the activation of protein kinase could explain the greater replicating potential of appMr 15,000 hIGF-II. Equilibrium dissociation, i.e. Kd, and inhibition, i.e. Ki, constants were determined by measuring the ability of rIGF-I, hIGF-II, appMr 15,000 hIGF-II, insulin, and the antireceptor monoclonal antibody alpha IR-3 to compete with 125I-labeled rIGF-I and hIGF-II for binding to purified preparations of IGF-I receptors prepared from an enriched source of fetal membrane, i.e. human term placenta. The results of these experiments established that 1) hIGF-II and appMr 15,000 hIGF-II bind to the IGF-I receptor with the same affinity as rIGF-I, e.g. with Kd and Ki values between 0.03-0.07 nM; 2) the total binding capacity, i.e. Ro, for IGF-I binding was not statistically different from the Ro calculated for IGF-II binding; and 3) the statistical analysis of 12 data sets from the competitive binding experiments for goodness of fit indicated that a 1-site model for IGF-I and -II binding was a better fit of the data than a 2-site model. Measurements of the stimulation of IGF-I receptor autophosphorylation at low ligand concentrations established that appMr 15,000 hIGF-II and hIGF-II were more effective than rIGF-I in coupling receptor occupancy to the activation of its protein kinase. At saturating ligand concentrations, the 3 had similar potencies. The original preparation of appMr 15,000 hIGF-II contains a mixture of forms with acidic isoelectric points (pIs) and was more potent than Mr 7,500 IGF-II in stimulating receptor autophosphorylation. These results are consistent with the relative potencies of this preparation, hIGF-II, and rIGF-I in stimulating the replication of 12-week-old fetal dermal fibroblasts.(ABSTRACT TRUNCATED AT 400 WORDS)
在本实验室报道的一项研究中,对于源自人胎儿的成纤维细胞,表观分子量(appMr)为15,000的人胰岛素样生长因子-II(hIGF-II)前体形式的促有丝分裂能力显示大于完全加工后的hIGF-II,并且两者都比重组IGF-I(rIGF-I)更具效力。由于人们普遍认为IGF对细胞复制的刺激是由IGF-I受体介导的,我们着手确定受体对hIGF-II的两种分子量形式和重组IGF-I(rIGF-I)的亲和力差异,或者其将特定生长因子占据与蛋白激酶激活偶联的效率差异,是否可以解释appMr 15,000 hIGF-II更大的复制潜力。通过测量rIGF-I、hIGF-II、appMr 15,000 hIGF-II、胰岛素和抗受体单克隆抗体αIR-3与125I标记的rIGF-I和hIGF-II竞争结合从富含胎儿膜的来源即人足月胎盘制备的纯化IGF-I受体制剂的能力,来确定平衡解离常数(即Kd)和抑制常数(即Ki)。这些实验结果表明:1)hIGF-II和appMr 15,000 hIGF-II与IGF-I受体结合的亲和力与rIGF-I相同,例如Kd和Ki值在0.03 - 0.07 nM之间;2)IGF-I结合的总结合容量(即Ro)与IGF-II结合计算出的Ro在统计学上无差异;3)对竞争结合实验的12个数据集进行拟合优度的统计分析表明,IGF-I和-II结合的1位点模型比2位点模型更适合数据。在低配体浓度下对IGF-I受体自身磷酸化刺激的测量表明,appMr 15,000 hIGF-II和hIGF-II在将受体占据与蛋白激酶激活偶联方面比rIGF-I更有效。在饱和配体浓度下,三者效力相似。appMr 15,000 hIGF-II的原始制剂包含具有酸性等电点(pI)的多种形式的混合物,并且在刺激受体自身磷酸化方面比Mr 7,500 IGF-II更有效。这些结果与该制剂、hIGF-II和rIGF-I在刺激12周龄胎儿真皮成纤维细胞复制方面的相对效力一致。(摘要截短于400字)